Jonathan Wygant, who serves as Vice President and Chief Accounting Officer at VERACYTE, INC. (NASDAQ:VCYT), executed a series of stock transactions on May 22, 2026. Specifically, Mr. Wygant sold 24,000 shares of the company's common stock for a total value of $1,089,624. These sales were conducted subsequent to an exercise of existing stock options.
The realized sale prices for these shares varied between $45.07 and $45.69, resulting in a calculated weighted average sale price of $45.401 per share. On the same day, Mr. Wygant simultaneously acquired 24,000 shares of VERACYTE common stock by exercising fully vested stock options at a cost of $24.80 per share, totaling $595,200.
Following these combined activities, Jonathan Wygant's direct holdings in VERACYTE, INC. common stock amount to 45,434 shares. This report on insider activity is viewed alongside broader company metrics: Veracyte shares have achieved a 58% return over the past year. However, current trading data indicates that the stock trades at a Price-to-Earnings (P/E) ratio of 41.29.
The recent transactions take place amidst several notable corporate developments for Veracyte Inc. The company recently released its first-quarter earnings report for 2026, which demonstrated substantial strength and significantly exceeded market expectations. Financially, the company reported an Earnings Per Share (EPS) of $0.52. This figure represented a considerable surprise relative to the analyst forecast of $0.33, marking a 57.58% beat. Revenue figures also surpassed projections, reaching $139.07 million when analysts had anticipated $130.15 million.
These strong financial outcomes signal a robust operational start for Veracyte into the year. Beyond its financial performance, Veracyte announced a critical regulatory and product milestone. The company's TrueMRD Monitoring Test for muscle-invasive bladder cancer secured coverage from the Centers for Medicare & Medicaid Services Molecular Diagnostics Services Program. This new coverage status is set to permit clinicians to order the test beginning June 1, 2026. This date marks the commercial launch of Veracyte’s first molecular residual disease offering, highlighting significant advancements in both the company's financial health and its product pipeline.
The current market valuation data for VCYT shows a closing price near $44.50 (up 0.29% during trading hours). While the strong earnings and new coverage are positive indicators, external analysis from InvestingPro suggests that, relative to its Fair Value, the stock may appear overvalued. Investors interested in deeper company insights can access comprehensive research through the Pro Research Report, which covers VCYT and over 1,400 other US equities.